Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 10Esophageal Squamous Cell Carcinoma 9Stomach Neoplasms 8Esophageal Neoplasms 6Pancreatic Neoplasms 5Colorectal Neoplasms 5Cholangiocarcinoma 3Biliary Tract Neoplasms 3Liver Neoplasms 2Gallbladder Neoplasms 2Digestive System Neoplasms 2Colonic Neoplasms 2SHR-1210 1Pancreatic Adenocarcinoma Metastatic 1Neuroendocrine Tumors 1Gastrointestinal Stromal Tumors 1Gastroenteropancreatic Neuroendocrine Tumor G3 1Breast Neoplasms 1Bile Duct Neoplasms 1Anlotinib 1

Interventions

spartalizumab 1sapropterin 1penpulimab 1niraparib 1anlotinib 1Taxes 1Leucovorin 1Ipilimumab 1IFL protocol 1Gemcitabine 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Adenocarcinoma Metastatic × anlotinib × Gastrointestinal × Clear all
NCT06051851 2023-09-25

RCT-PAAG

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Recruiting
177 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡